Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $1.9 million.

  • Cytek Biosciences' Depreciation & Amortization (CF) rose 361.97% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 784.09%. This contributed to the annual value of $7.2 million for FY2024, which is 1924.6% up from last year.
  • Cytek Biosciences' Depreciation & Amortization (CF) amounted to $1.9 million in Q3 2025, which was up 361.97% from $1.9 million recorded in Q2 2025.
  • Cytek Biosciences' 5-year Depreciation & Amortization (CF) high stood at $1.9 million for Q3 2025, and its period low was $72000.0 during Q3 2022.
  • Over the past 5 years, Cytek Biosciences' median Depreciation & Amortization (CF) value was $1.6 million (recorded in 2023), while the average stood at $1.2 million.
  • In the last 5 years, Cytek Biosciences' Depreciation & Amortization (CF) crashed by 6190.48% in 2022 and then soared by 235416.67% in 2023.
  • Over the past 5 years, Cytek Biosciences' Depreciation & Amortization (CF) (Quarter) stood at $685000.0 in 2021, then increased by 11.09% to $761000.0 in 2022, then skyrocketed by 114.32% to $1.6 million in 2023, then increased by 13.67% to $1.9 million in 2024, then rose by 3.45% to $1.9 million in 2025.
  • Its Depreciation & Amortization (CF) was $1.9 million in Q3 2025, compared to $1.9 million in Q2 2025 and $1.9 million in Q1 2025.